Debiopharm Group
VC Fund
Lausanne, Switzerland
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Debiopharm Group invests in
Stages Debiopharm Group invests in
Countries Debiopharm Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3.4M–$17M
- Series B
- $11M–$33M
Investment Focus
Industry
- Health Care 4 (22%)
- Health Diagnostics 4 (22%)
- Biotechnology 3 (17%)
- Pharmaceutical 3 (17%)
- Artificial Intelligence 3 (17%)
Stage
- Seed 4 (22%)
- Funding Round 4 (22%)
- Series B 3 (17%)
- Series A 2 (11%)
- Series C 1 (6%)
Country
- Switzerland 5 (28%)
- Canada 2 (11%)
- France 1 (6%)
- Germany 1 (6%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Thierry Mauvernay
President & Delegate of the Board
|
President & Delegate of the Board | Total investments: 8 | Find email | |
Alexandra Le Coz Sanchez
Associate Director, Private Equity Department, Debiopharm Investment S.A.
|
Associate Director, Private Equity Department, Debiopharm Investment S.A. | Total investments: 1 | Find email | |
ANGELA ZUBEL
Chief Development Officer
|
Chief Development Officer | Total investments: 0 | Find email | |
Bertrand Ducrey
CEO
|
CEO | Total investments: 0 | Find email | |
Raymond Zaugg
Director, Financial department, Debiopharm Investment S.A
|
Director, Financial department, Debiopharm Investment S.A | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ViewsML
|
ViewsML leverages artificial intelligence to enhance virtual diagnostics and precision medicine. The company focuses on transforming spatial biology and translational research by utilizing virtual biomarkers. Their technology aims to improve patient outcomes by providing deeper insights into healthcare diagnostics. ViewsML is involved in developingimmunohistochemistry technology to streamline the diagnostic process and support research objectives efficiently. | $4.9M / Seed / Apr 20, 2026 | |
StratifAI
|
Building the next generation of biomarkers for precision oncology | $14.7M / Sep 30, 2025 | |
Raidium
|
Raidium is a Medtech startup that is developing the first-ever radiological foundation model, as the “GPT-4” of radiology. This new generation of AI will enable the building of an imaging biomarker factory for both clinical practice and research, to tackle the complexity of precision medicine. | $16.9M / Seed / Nov 28, 2024 | |
Tune Insight
|
Tune Insight orchestrates secure collaborations on sensitive data between multiple organizations to extract collective insights. | $3.4M / Seed / Sep 28, 2023 | |
WhiteLab Genomics
|
WhiteLab Genomics develops digital tools that help gene and cell therapy companies develop cheaper drugs faster. | $10M / Seed / Sep 12, 2022 | |
Coorpacademy
|
Coorpacademy offers a range of innovative learning solutions and MOOCs. It was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre in 2013 and is based in Lausanne, Switzerland. | $11M / Series B / Oct 26, 2016 | |
GenePOC
|
GenePOC Inc. is a privately owned company, member of Debiopharm Group, that develops accurate and cost-effective molecular solutions to detect pathogen genes. GenePOC has developed a simple and stand-alone system for the prevention and early detection of infectious diseases based on a unique microfluidic technology. | Jan 13, 2015 | |
|
Coorpacademy
|
Coorpacademy offers a range of innovative learning solutions and MOOCs. It was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre in 2013 and is based in Lausanne, Switzerland. | $3.5M / Series A / Nov 17, 2014 | |
Immunexpress
|
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; andthe translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington. | $6M / Mar 05, 2014 | |
Urturn
|
Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or joinin with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn... | $13.4M / Series A / May 22, 2013 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Debiopharm Group invest in?
Debiopharm Group invests primarily in Health Care, Health Diagnostics and Biotechnology startups, most often at Seed and Funding Round stage. Most of the 18 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Debiopharm Group's check size?
Debiopharm Group typically joins rounds of $3.4M–$17M at Seed and $11M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Debiopharm Group participates in.
How do I contact Debiopharm Group?
Public channels for Debiopharm Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Debiopharm Group?
The team at Debiopharm Group includes Thierry Mauvernay (President & Delegate of the Board), Alexandra Le Coz Sanchez (Associate Director, Private Equity Department, Debiopharm Investment S.A.) and ANGELA ZUBEL (Chief Development Officer), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
